Brookstone Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,264
| Closed | -$1.1M | – | 1100 |
|
|
2025
Q1 | $1.1M | Sell |
2,264
-56
| -2% | -$27.2K | 0.02% | 532 |
|
|
2024
Q4 | $934K | Sell |
2,320
-2
| -0.1% | -$805 | 0.01% | 550 |
|
|
2024
Q3 | $1.08M | Sell |
2,322
-169
| -7% | -$78.6K | 0.02% | 508 |
|
|
2024
Q2 | $1.22M | Buy |
2,491
+123
| +5% | +$60.1K | 0.02% | 464 |
|
|
2024
Q1 | $990K | Buy |
2,368
+237
| +11% | +$99.1K | 0.02% | 492 |
|
|
2023
Q4 | $867K | Sell |
2,131
-1,206
| -36% | -$491K | 0.02% | 488 |
|
|
2023
Q3 | $1.22M | Buy |
3,337
+1,208
| +57% | +$441K | 0.03% | 392 |
|
|
2023
Q2 | $720K | Sell |
2,129
-34
| -2% | -$11.5K | 0.01% | 496 |
|
|
2023
Q1 | $709K | Sell |
2,163
-232
| -10% | -$76.1K | 0.01% | 521 |
|
|
2022
Q4 | $695K | Buy |
2,395
+1,681
| +235% | +$488K | 0.01% | 514 |
|
|
2022
Q3 | $207K | Buy |
+714
| New | +$207K | ﹤0.01% | 742 |
|
|
2021
Q3 | – | Sell |
-1,151
| Closed | -$228K | – | 789 |
|
|
2021
Q2 | $228K | Buy |
+1,151
| New | +$228K | ﹤0.01% | 651 |
|
|
2020
Q3 | – | Sell |
-4,055
| Closed | -$1.18M | – | 471 |
|
|
2020
Q2 | $1.18M | Buy |
+4,055
| New | +$1.18M | 0.07% | 158 |
|
|
2015
Q4 | – | Sell |
-13
| Closed | -$1K | – | 867 |
|
|
2015
Q3 | $1K | Hold |
13
| – | – | ﹤0.01% | 1856 |
|
|
2015
Q2 | $2K | Buy |
+13
| New | +$2K | ﹤0.01% | 1837 |
|